Literature DB >> 30863602

Minimally invasive lobectomy with neoadjuvant targeted therapy: the Zhejiang Cancer Hospital experience.

Taobo Luo1, Jian Zeng1.   

Abstract

Entities:  

Year:  2019        PMID： 30863602      PMCID： PMC6384331          DOI： 10.21037/jtd.2018.12.100

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  17 in total

1.  Patterns of surgical care of lung cancer patients.

Authors:  Alex G Little; Valerie W Rusch; James A Bonner; Laurie E Gaspar; Mark R Green; W Richard Webb; Andrew K Stewart
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

Review 2.  Non-small-cell lung cancer.

Authors:  Peter Goldstraw; David Ball; James R Jett; Thierry Le Chevalier; Eric Lim; Andrew G Nicholson; Frances A Shepherd
Journal:  Lancet       Date:  2011-05-10       Impact factor: 79.321

3.  Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.

Authors:  Humberto Lara-Guerra; Catherine T Chung; Joerg Schwock; Melania Pintilie; David M Hwang; Natasha B Leighl; Thomas K Waddell; Ming-Sound Tsao
Journal:  Lung Cancer       Date:  2011-11-22       Impact factor: 5.705

4.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis.

Authors:  M K Gould; C C Maclean; W G Kuschner; C E Rydzak; D K Owens
Journal:  JAMA       Date:  2001-02-21       Impact factor: 56.272

5.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

Review 6.  Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care.

Authors:  Athanasios G Pallis; Vassilis Georgoulias
Journal:  Lung Cancer       Date:  2011-10-11       Impact factor: 5.705

7.  Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer.

Authors:  Eva E Schaake; Ingrid Kappers; Henk E Codrington; Renato A Valdés Olmos; Hendrik J Teertstra; Renée van Pel; Jacobus A Burgers; Harm van Tinteren; Houke M Klomp
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

8.  Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.

Authors:  Herbert Decaluwé; Paul De Leyn; Johan Vansteenkiste; Christophe Dooms; Dirk Van Raemdonck; Philippe Nafteux; Willy Coosemans; Toni Lerut
Journal:  Eur J Cardiothorac Surg       Date:  2009-06-06       Impact factor: 4.191

Review 9.  PET/CT in the staging of the non-small-cell lung cancer.

Authors:  Fangfang Chao; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-07

Review 10.  The Utility of Metabolic Imaging by 18F-FDG PET/CT in Lung Cancer: Impact on Diagnosis and Staging.

Authors:  Abbas Yousefi-Koma; Mojgan Panah-Moghaddam; Victor Kalff
Journal:  Tanaffos       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.